SUL-238
/ Sulfateq, Gen Ilaç ve Saglik Ürünleri
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 26, 2024
A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=69 | Recruiting | Sponsor: GEN İlaç ve Sağlık Ürünleri A.Ş.
New P1 trial
1 to 1
Of
1
Go to page
1